Código QR (código de barras bidimensional)

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible pan-HER inhibitor, in combination with the multi-...

ver descrição completa

Na minha lista:
Principais autores: Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2024-11-01
coleção:Translational Oncology
Assuntos:
Breast cancer
HER2-positive
Targeted therapies
Tyrosine kinase inhibitors
Neratinib
Dasatinib
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S1936523324002006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados